1. 3300 A phase 1b/2 study of ribociclib (LEE011; CDK4/6 inhibitor) in combination with binimetinib (MEK162; MEK inhibitor) in patients with NRAS-mutant melanoma. (September 2015) Authors: Van Herpen, C.; Postow, M.A.; Carlino, M.S.; Kalkavan, H.; Weise, A.; Amaria, R.N.; Vos, F. De; Carvajal, R.D.; Matano, A.; Bhansali, S.; Lam, L.; Yerramilli-Rao, P.; Sosman, J.A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S663 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗